Requires health plan coverage to include generic drugs and biosimilars where the wholesale acquisition cost of such generic drugs or biosimilars is lower than the brand drug's wholesale acquisition cost.

This bill requires health insurance plans in New York to cover generic drugs and biosimilars if their wholesale acquisition cost is lower than that of the corresponding brand-name drugs. This means that patients could have better access to more affordable medication options. The goal is to encourage the use of less expensive alternatives to brand-name drugs.

Supporters of the bill argue that it will help lower healthcare costs for patients by ensuring that more affordable generic drugs and biosimilars are covered by insurance plans. They believe this will promote competition in the pharmaceutical market and ultimately lead to better health outcomes for consumers. This legislation is seen as a step towards making medications more accessible for all New Yorkers.

Critics of the bill may argue that it could undermine the incentives for pharmaceutical companies to invest in new drug development by reducing the profitability of brand-name drugs. They might also express concerns that requiring coverage for generics and biosimilars could lead to confusion among patients regarding their medication options. Additionally, there are worries that the quality and effectiveness of these alternatives might not always match that of the original brand-name drugs.